tiprankstipranks
Trending News
More News >

SpringWorks Therapeutics Announces Merger with Merck KGaA

Story Highlights
SpringWorks Therapeutics Announces Merger with Merck KGaA

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Springworks Therapeutics ( (SWTX) ) is now available.

On April 27, 2025, SpringWorks Therapeutics entered into a Merger Agreement with Merck KGaA, Darmstadt, Germany, and EMD Holdings Merger Sub, Inc., which will result in SpringWorks becoming a wholly owned subsidiary of Merck KGaA. The merger has received necessary approvals from the Bundeskartellamt and the expiration of the waiting period under the HSR Act, with the finalization expected in the second half of 2025, pending satisfaction of remaining conditions including stockholder approval.

The most recent analyst rating on (SWTX) stock is a Hold with a $47.00 price target. To see the full list of analyst forecasts on Springworks Therapeutics stock, see the SWTX Stock Forecast page.

Spark’s Take on SWTX Stock

According to Spark, TipRanks’ AI Analyst, SWTX is a Neutral.

Springworks Therapeutics holds potential due to its strong revenue growth and the strategic merger with Merck. However, ongoing profitability and cash flow challenges, coupled with a negative P/E ratio, weigh on the stock’s attractiveness. Technical indicators show upward momentum, but caution is advised due to potential overbought conditions.

To see Spark’s full report on SWTX stock, click here.

More about Springworks Therapeutics

SpringWorks Therapeutics, Inc. is a Delaware-based company operating in the biopharmaceutical industry, focusing on the development of medicines for patients with severe rare diseases and cancer.

Average Trading Volume: 5,151,250

Technical Sentiment Signal: Buy

Current Market Cap: $3.52B

Find detailed analytics on SWTX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1